Lessons from the withdrawal of rofecoxib: France has policy for overall assessment of public health impact of new drugs
AUTOR(ES)
Abenhaim, Lucien
FONTE
BMJ Publishing Group Ltd.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=534885Documentos Relacionados
- Lessons from the withdrawal of rofecoxib: Observational studies should not be forgotten
- Lessons from the withdrawal of rofecoxib: Patients would be safer if drug companies disclosed adverse events before licensing
- Public health activism: lessons from history?
- Lessons from the first twenty years of Medicare: research implications for public and private sector policy
- New dimensions of public health: their impact on the evaluation and selection of health personnel. II. A manpower strategy for public health.